Hypertension, Diabetes Mellitus, and Blood Groups in Benign Prostatic Hypertrophy

Bourke, J. B.; Griffin, Jasper

doi:10.1111/j.1464-410x.1966.tb09675.x

Cited by 61 publications

(36 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The fact that both BPH and metabolic syndrome are very common conditions -particularly among older men-and the observation that most BPH patients share similar metabolic abnormalities as patients with the metabolic syndrome, have led several investigators to point out a relationship between those two conditions (16,17). Although the specific mechanism is not clearly understood it could be assumed that it involves an interplay between several hormonal pathways: since lipids impact both on cardiovascular disease development and the production of sexual hormones, it is plausible that they might affect the risk for BPH development through the increase of DHT levels (18).…”

Section: Commentsmentioning

confidence: 99%

The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride

Stamatiou

Zaglavira

Skolarikos³

et al. 2008

Int. braz j urol.

View full text Add to dashboard Cite

Objective: To explore whether or not statins have any impact on the progression of components of benign prostatic hyperplasia (lower urinary tract symptoms severity, prostate volume and serum prostate specific antigen (PSA) when combined with other agents inhibiting growth of prostate cells. Materials and Methods:This was a preliminary, clinical study. Eligible patients were aged > 50 yrs, with International Prostate Symptom Score (IPSS) between 9 and 19, total prostate volume (TPV) > 40 mL, and serum PSA > 1.5 ng/mL. Patients were divided in two groups: those with and those without lipidemia. After selection, eligible BPH patients with lipidemia (n = 18) were prescribed lovastatin 80 mg daily and finasteride 5 mg daily, while eligible patients without lipidemia (n = 15) were prescribed only finasteride 5 mg daily. IPSS, TPV and serum PSA were evaluated at end point (4 months).Results: There was no difference between the two groups on the primary end point of mean change from baseline in IPSS (p = 0.69), TPV (p = 0.90) and PSA (p = 0.16) after 4 months of treatment. Conclusions: Short-term lovastatin treatment does not seem to have any effect on IPSS, TPV and PSA in men with prostatic enlargement due to presumed BPH.

show abstract

Section: Commentsmentioning

confidence: 99%

The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride

Stamatiou

Zaglavira

Skolarikos³

et al. 2008

Int. braz j urol.

View full text Add to dashboard Cite

show abstract

“…11 Daniell 12 found increased specimen weights with increasing obesity in men subjected to transurethral resection of the prostate. However, Sidney et al 13 reported that surgery for BPH was performed less frequently among overweight men and Glynn et al 14 reported that obese men were less likely than lean men to have a clinical diagnosis of BPH based on symptoms and digital rectal examination.…”

Section: Introductionmentioning

confidence: 99%

Components of the metabolic syndrome—risk factors for the development of benign prostatic hyperplasia

Hammarsten

Högstedt

Holthuis³

et al. 1998

Prostate Cancer Prostatic Dis

267

220

View full text Add to dashboard Cite

The purpose of the present study was to perform a BPH risk factor analysis in men, relating the prostate gland volume to components of the metabolic syndrome and to identify clues to the etiology of BPH.Our material comprised a consecutive series of 158 patients with lower urinary tract symptoms with or without manifestations of the metabolic syndrome. In this group, the measured volume of the prostate was related consecutively to potential risk factors. The diagnoses atherosclerosis, non-insulin-dependent diabetes mellitus (NIDDM) and treated hypertension were obtained from the patient's medical history. Data on blood pressure, waist and hip measure, body height and weight were collected and body mass index (BMI) and waist/hip ratio (WHR) were calculated. Blood samples were drawn from fasting patients to determine insulin, cholesterol, triglycerides, HDL and LDL-cholesterol, uric acid and ALAT. The prostate gland volume was determined using ultrasound.Our results show that there was a larger prostate gland in men with NIDDM (P 0.0058), treated hypertension (P 0.0317), obesity (P`0.0001), low HDLcholesterol levels (P 0.0132) and high insulin levels (P`0.0001) than in men without these conditions. The prostate gland volume correlated positively with the systolic blood pressure (r s 0.17; P 0.03), obesity (r s 0.34; P`0.0001) and fasting insulin (r s 0.38; P`0.0001) and negatively with HDL-cholesterol (r s À0.22; P 0.009).On the basis of our ®ndings, we concluded that NIDDM, treated hypertension, obesity, low HDL-cholesterol levels and high insulin levels constitute risk factors for the development of BPH. The results suggest that BPH is a facet of the metabolic syndrome and that BPH patients may share the same metabolic abnormality of a defective insulin-mediated glucose uptake and secondary hyperinsulinemia as patients with the metabolic syndrome. The ®ndings generate a hypothesis of a causal relationship between high insulin levels and the development of BPH. In a clinical setting, the ®ndings of the present report suggest that, in any patient presenting with BPH, the possible presence of NIDDM, hypertension, obesity, high insulin and low HDL-cholesterol levels should be considered. Conversely, in patients suffering from these conditions, the possibility of a clinically important BPH should be kept in mind.

show abstract

“…Some studies have suggested a role of diabetes or hypertension in the pathogenesis of PBH (1). Further, HDL-cholesterol levels were an independent predictors of prostate enlargement (2).…”

Section: Introductionmentioning

confidence: 99%

Risk factors for benign prostatic enlargement: The role of lifestyle habits at younger age. The #Controllati2017 initiative study group

Mirone

Carrieri

Morgia

et al. 2017

Arch Ital Urol Androl

View full text Add to dashboard Cite

Objective: The risk factors for benign prostatic enlargement (BPE) are not well understood and particularly few data are available from Italian population. Materials and methods: This was an observational cross sectional study aimed to examine the association between several risk factors and BPE. During the “#Controllati2017” initiative, men aged 18 years or more were invited to attend participating urologic centers for a free of charge visit for counseling about urologic or andrologic conditions. Each participating man underwent a physical examination including digital rectal examination (DRE). Further he was asked about his medical history, urologic symptoms, sexual activity and related problems. Diagnosis of BPE was made by the urologist after DRE. Results: Out of the 1902 [mean age 54 years (SD 12, range 18-92)] considered men, a total of 603 subjects (31.7%) had diagnosis of BPE. The diagnosis of BPE increased from 9.3% in men aged < = 50 years, to 34.1% in those aged 51-60 years and to 58.7% among men aged > 60 years. A history of hypertension, diabetes, heart diseases, hypercholesterolemia and hypertriglyceridemia were all significantly associated with an increased risk of BPE in the total series and, although not always in a statistically significant way, in strata of age. Physical activity (PA) was significantly associated with a decreased risk of BPE. We have further analyzed the risk of BPE in men with one or more of the identified risk factors (i.e. hypertension, diabetes, heart disease, hypercholesterolemia, hypertriglyceridemia and low PA): the risk of BPE increased with number of risk factors reported by the subjects. The estimated risk were higher among younger men. Conclusion: In our study a history of hypertension, diabetes, heart disease, hypercholesterolemia and hypertriglyceridemia increased the risk and physical activity lowered the risk of BPE. This risk profile was observed also in men aged < 50 years.

show abstract

Hypertension, Diabetes Mellitus, and Blood Groups in Benign Prostatic Hypertrophy

Cited by 61 publications

References 21 publications

The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride

The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride

Components of the metabolic syndrome—risk factors for the development of benign prostatic hyperplasia

Risk factors for benign prostatic enlargement: The role of lifestyle habits at younger age. The #Controllati2017 initiative study group

Contact Info

Product

Resources

About